318 related articles for article (PubMed ID: 35092511)
41. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
42. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
43. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
44. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
45. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.
Zhu W; Wu C; Hu S; Liu S; Zhao S; Zhang D; Qiu G; Cheng X; Huang J
Sci Rep; 2023 Dec; 13(1):21358. PubMed ID: 38049474
[TBL] [Abstract][Full Text] [Related]
46. The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit.
Hou Y; Qiao S; Li M; Han X; Wei X; Pang Y; Mao H
Front Genet; 2022; 13():1090640. PubMed ID: 36704336
[TBL] [Abstract][Full Text] [Related]
47. Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.
Xu M; Ma X; Wang Y; Yu Z; Zheng X; Dai H; Xue C
J Cancer Res Clin Oncol; 2024 Jun; 150(6):313. PubMed ID: 38900244
[TBL] [Abstract][Full Text] [Related]
48. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
49. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
Front Immunol; 2021; 12():690105. PubMed ID: 34054879
[TBL] [Abstract][Full Text] [Related]
50. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
51. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
[TBL] [Abstract][Full Text] [Related]
52. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
Zou W; Li L; Wang Z; Jiang N; Wang F; Hu M; Liu R
Bioengineered; 2021 Dec; 12(1):9006-9020. PubMed ID: 34654352
[TBL] [Abstract][Full Text] [Related]
53. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
[TBL] [Abstract][Full Text] [Related]
54. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
55. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
56. The association of immune cell infiltration and prognostic value of tertiary lymphoid structures in gastric cancer.
Yu JS; Huang WB; Zhang YH; Chen J; Li J; Fu HF; Wei ZW; He YL
Neoplasma; 2022 Jul; 69(4):886-898. PubMed ID: 35603954
[TBL] [Abstract][Full Text] [Related]
57. The molecular subtypes and clinical prognosis characteristic of tertiary lymphoid structures-related gene of cutaneous melanoma.
Li J; Chen G; Luo Y; Xu J; He J
Sci Rep; 2023 Dec; 13(1):23097. PubMed ID: 38155221
[TBL] [Abstract][Full Text] [Related]
58. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive analysis of tertiary lymphoid structures-related genes for prognostic prediction, molecular subtypes and immune infiltration in gastric cancer.
Zhou Q; Lan L; Wang W; Xu X; Wang W
Aging (Albany NY); 2023 Nov; 15(22):13368-13383. PubMed ID: 38015717
[TBL] [Abstract][Full Text] [Related]
60. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
